Literature DB >> 14594232

Potential treatment of fatty liver with 14-day subcutaneous injections of glucagon.

G Bobe1, B N Ametaj, J W Young, D C Beitz.   

Abstract

Fatty liver is a major metabolic disease of dairy cows in early lactation that can be treated with 14-d continuous, intravenous infusions of 10 mg/d of glucagon. The objective was to test whether similar effects can be obtained with 14-d subcutaneous 7.5- or 15-mg daily dosages of glucagon beginning at d 8 postpartum. Multiparous Holstein cows (n = 32) were grouped on the basis of their liver triacylglycerol concentration at d 8 postpartum into "normal" (n = 8; triacylglycerol < 1% liver wet wt) and "susceptible" (n = 24; triacylglycerol > 1% liver wet wt) cows. Susceptible cows were assigned randomly to three groups and beginning at d 8 postpartum received 0, 2.5, or 5 mg of glucagon in 60 ml of saline by subcutaneous injections every 8 h for 14 d. Beginning at d 8 postpartum, normal cows received 60 ml of saline by subcutaneous injections every 8 h for 14 d. Both dosages of glucagon increased concentrations of plasma glucose and insulin and decreased concentrations of plasma nonesterfied fatty acids. Glucagon injections of 15 mg/d decreased concentrations of liver triacylglycerol in cows older than 3.5 yr, but not in younger multiparous cows. Our results document that subcutaneous injections of glucagon have the potential to decrease the degree of fatty liver in older dairy cows in early lactation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14594232     DOI: 10.3168/jds.S0022-0302(03)73915-0

Source DB:  PubMed          Journal:  J Dairy Sci        ISSN: 0022-0302            Impact factor:   4.034


  5 in total

1.  The glucagon receptor is required for the adaptive metabolic response to fasting.

Authors:  Christine Longuet; Elaine M Sinclair; Adriano Maida; Laurie L Baggio; Marlena Maziarz; Maureen J Charron; Daniel J Drucker
Journal:  Cell Metab       Date:  2008-11       Impact factor: 27.287

2.  Hepatocyte apoptosis in dairy cattle during the transition period.

Authors:  Mohamed Tharwat; Aya Takamizawa; Yoshinao Z Hosaka; Daiji Endoh; Shin Oikawa
Journal:  Can J Vet Res       Date:  2012-10       Impact factor: 1.310

Review 3.  The metabolic actions of glucagon revisited.

Authors:  Kirk M Habegger; Kristy M Heppner; Nori Geary; Timothy J Bartness; Richard DiMarchi; Matthias H Tschöp
Journal:  Nat Rev Endocrinol       Date:  2010-10-19       Impact factor: 43.330

4.  Glucagon is associated with NAFLD inflammatory progression in type 2 diabetes, not with NAFLD fibrotic progression.

Authors:  Yuying Wang; Zhiqi Lin; Heng Wan; Wen Zhang; Fangzhen Xia; Yi Chen; Xiaoman Chen; Chiyu Wang; Chi Chen; Ningjian Wang; Yingli Lu
Journal:  Eur J Gastroenterol Hepatol       Date:  2021-12-01       Impact factor: 2.586

5.  Butaphosphan Effects on Glucose Metabolism Involve Insulin Signaling and Depends on Nutritional Plan.

Authors:  Maria Amélia Agnes Weiller; Joao Alveiro Alvarado-Rincón; Carolina Bespalhok Jacometo; Carlos Castilho Barros; Izabel Cristina Custódio de Souza; Lucas Teixeira Hax; Thaís Casarin da Silva; Patrícia Mattei; Antônio Amaral Barbosa; Josiane de Oliveira Feijó; Rubens Alves Pereira; Cassio Cassal Brauner; Viviane Rohrig Rabassa; Francisco Augusto Burkert Del Pino; Marcio Nunes Corrêa
Journal:  Nutrients       Date:  2020-06-22       Impact factor: 5.717

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.